What Is Chronic Spontaneous Urticaria (Chronic Hives)?

Chronic spontaneous urticaria (CSU) is a condition in which itchy, raised welts (hives) and sometimes deeper tissue swelling keep appearing on the skin for more than six weeks, without any identifiable external trigger like a food allergy or physical pressure. It is driven by overactive mast cells in the skin that release histamine and other inflammatory chemicals on their own, and researchers now believe the immune system itself is usually to blame. CSU can persist for years, overlap with anxiety and thyroid disease, and resist standard allergy pills, which makes it far more complex than the “just hives” label suggests.

What Actually Happens in the Skin

The welts and itching of CSU come down to one cell type gone haywire: the mast cell. Mast cells sit in the skin and normally stay quiet until a real threat appears. In CSU, they activate and dump their contents, especially histamine, without any outside allergen telling them to do so.¹ That burst of histamine is what makes blood vessels leak fluid into surrounding tissue, producing the raised, red, intensely itchy wheals that are the hallmark of the disease.

Why those mast cells go off is where the science has evolved considerably in recent years. Researchers have identified two major autoimmune pathways. In the first, called the type I or “autoallergic” endotype, the body produces IgE antibodies that mistakenly target its own proteins, such as thyroid peroxidase. Those self-directed IgE antibodies sit on mast cells and trigger degranulation just as if a real allergen had arrived. In the second pathway, the type IIb or “autoimmune” endotype, IgG autoantibodies attack either IgE itself or the receptor IgE docks on (FcεRI), causing mast cells to fire.² Not every patient fits neatly into one of these two categories, but the discovery of these endotypes has reshaped how specialists think about treatment, because the two groups can respond differently to different drugs.

Symptoms Beyond the Itch

The defining symptom is the wheal itself: a pink or red swelling that appears suddenly, itches fiercely, and usually fades within a few hours to a day, only to pop up somewhere else. Individual hives come and go, but new ones keep forming so the cycle feels endless. Around 40% of people with CSU also experience angioedema, a deeper swelling that tends to hit the lips, eyelids, hands, or feet. Another roughly 10% have angioedema as their main symptom with few or no surface hives at all.³

Angioedema episodes can be alarming, particularly when the swelling distorts the face or makes swallowing feel tight. The unpredictability makes daily life stressful: a person may wake up clear-skinned and be covered in welts by lunch, or have weeks of relative calm followed by an explosive flare for no obvious reason.⁴

How CSU Is Diagnosed

There is no single blood test that confirms CSU. Diagnosis is largely clinical: recurrent wheals, angioedema, or both lasting more than six weeks with no clear external cause. A key part of the evaluation is ruling out chronic inducible urticaria, which looks similar but has identifiable physical triggers such as cold, pressure, sunlight, or vibration. Both types can coexist in the same patient, which complicates things.⁵

One important mimic to exclude is urticarial vasculitis. If individual wheals last longer than 24 hours, leave behind bruising or dark marks when they resolve, or come with systemic symptoms like joint pain, abdominal pain, or fever, experts recommend a skin biopsy. The pathologist looks for specific signs of blood vessel inflammation, including a pattern called leukocytoclasia and fibrin deposits in vessel walls. Lab work for anti-nuclear antibodies and C-reactive protein can help round out the picture.⁶ If your hives always vanish within a day and leave no mark, vasculitis is unlikely, and a biopsy is usually unnecessary.

Conditions That Travel With CSU

CSU rarely shows up alone. A 2024 JAMA review found that it persists beyond one year in most patients and commonly brings along other diagnoses: chronic inducible urticaria in more than 10% of cases, autoimmune thyroiditis in roughly 20%, metabolic syndrome in 6 to 20%, and significant anxiety in 10 to 31% and depression in 7 to 29%.⁷

The thyroid connection is especially well documented. A systematic review found strong evidence that IgG antibodies against thyroid peroxidase are elevated in CSU patients far more often than in the general population, with rates of 10% or higher across most studies. Hypothyroidism and Hashimoto’s thyroiditis are more common than hyperthyroidism and Graves’ disease in this group.⁸ This overlap makes sense in light of the autoallergic endotype described earlier, where IgE directed at thyroid peroxidase is one of the identified autoantigens. Screening thyroid function is now standard practice when someone is diagnosed with CSU.

The Toll on Sleep, Mood, and Daily Life

The quality-of-life hit from CSU is often underestimated. The itch peaks at night for many people, disrupting sleep onset and total sleep duration. One study found that CSU patients had significantly longer time to fall asleep, shorter total sleep, and lower sleep efficiency compared to healthy controls. In that same cohort, 92% screened positive for anxiety and 72% for depression.⁹ A separate cross-sectional study found anxiety in about 47% and depression in about 41% of CSU patients, confirming that emotional distress is a consistent part of the picture even when the specific rates vary between studies.¹⁰

Beyond the numbers, the experience of visible hives that can appear at any time leads many people to cancel plans, avoid social situations, or dread work meetings. It is a skin condition that functions like a chronic pain condition in terms of its psychological and social burden.

The Financial Weight

CSU is expensive to live with. A multinational real-world study (the ASSURE-CSU study) tracked costs across several European countries and found that average annual direct medical costs per patient ranged from about $900 in Italy to nearly $3,000 in France, driven mostly by medications and inpatient visits. Indirect costs from lost work productivity added substantially more, with presenteeism (being at work but unable to function fully) accounting for the majority of lost output.¹¹ For patients who cycle through multiple specialists and treatments before finding one that works, cumulative out-of-pocket costs can be considerable.

First-Line Treatment and Updosing

The standard starting treatment is a second-generation, non-sedating antihistamine such as cetirizine, loratadine, or fexofenadine, taken daily. Guidelines specifically recommend against the older, sedating first-generation antihistamines because they cause drowsiness without better efficacy. If a standard dose does not control symptoms, the next step is not switching drugs but rather increasing the dose of the same antihistamine up to four times the licensed amount.¹² That may sound extreme, but it is well studied and generally well tolerated, though some patients report increased sleepiness at higher doses.¹³

Despite updosing, a significant portion of patients still do not achieve adequate control. Estimates vary, but the need for additional therapy beyond antihistamines is common enough that guidelines include a clear stepwise algorithm moving beyond this point.

Omalizumab and Beyond

For antihistamine-refractory CSU, omalizumab (brand name Xolair) has been the go-to biologic since its approval for the condition over a decade ago. It is a monoclonal antibody that binds free IgE in the blood, depleting the supply. Without IgE coating their surfaces, mast cells gradually become less reactive and harder to trigger.¹⁴ Skin biopsies in treated patients show that the number of cells expressing the high-affinity IgE receptor drops significantly within weeks of starting therapy.¹⁵

Omalizumab at 300 mg every four weeks is among the most effective options available, with a network meta-analysis showing it reduced disease activity scores by about 10 points more than placebo. Cyclosporine at 3 to 5 mg/kg daily showed a similar magnitude of benefit but came with roughly double the odds of side effects compared to omalizumab, which had side-effect rates essentially equivalent to placebo.¹⁶ Cyclosporine, an immunosuppressant, is generally reserved for cases that do not respond to omalizumab, and its use requires monitoring for kidney function and blood pressure.¹⁷

Emerging Therapies Reshaping the Landscape

The treatment pipeline for CSU has expanded rapidly. Phase 3 trials of dupilumab, a biologic already widely used for eczema and asthma, showed significant improvements in itch and hive scores compared to placebo at 24 weeks in the LIBERTY-CSU CUPID trials.¹⁸ Real-world data have similarly suggested benefit when dupilumab is added to existing therapy.¹⁹

Beyond dupilumab, a new class of oral drugs called Bruton’s tyrosine kinase (BTK) inhibitors, including remibrutinib and rilzabrutinib, is generating excitement. Rather than blocking a single antibody like omalizumab does, BTK inhibitors shut down a signaling step inside mast cells and basophils, making it harder for those cells to activate in the first place. Another approach targets KIT, a receptor on the mast cell surface, with the antibody barzolvolimab. In phase 2 trials, barzolvolimab achieved complete response rates of 38 to 51% at 12 weeks. Dupilumab and remibrutinib showed complete response rates of 30 to 32% and 28 to 32% respectively in their phase 3 programs at 24 weeks.²⁰ These numbers represent genuinely new options for patients stuck on medications that provide only partial relief.

How Long CSU Lasts

CSU is considered self-limiting, but the timeline can be frustratingly long. A five-year prospective study tracked patients and found that only about 10% reached remission in the first year. By the end of five years, cumulative remission reached roughly 59%. About 17% of patients who initially improved experienced a recurrence, and around 12% transitioned from full hives to a state of persistent itch without visible wheals.²¹ In other words, while the odds of eventual improvement are in your favor, the condition frequently lingers for multiple years. A targeted literature review confirmed that the disease duration is highly variable and depends on factors that are not fully pinned down.²²

Biomarkers and the Push Toward Personalized Treatment

Because CSU has distinct endotypes that respond differently to therapy, there is growing interest in blood tests that can guide treatment choices rather than relying on trial and error. Biomarkers such as total IgE levels, C-reactive protein, and basophil counts have shown some ability to predict disease severity and how a patient will respond to a given drug. Newer markers including FcεRI expression levels, IL-6, and D-dimer are being investigated for additional insight.²³ The goal is to match patients to the right biologic or oral therapy early, rather than cycling through months of ineffective treatment. Endotyping and biomarker profiling are not yet routine in most clinics, but the concept is moving from research toward clinical use.²⁴

CSU During Pregnancy

Pregnancy adds a layer of complexity. The PREG-CU study, the first to examine this directly, found that CSU improved during pregnancy in about half of patients but worsened in a third, with two out of five experiencing flare-ups during pregnancy. International guidelines recommend the same stepwise approach used in non-pregnant patients: start with standard-dose second-generation antihistamines, updose up to four-fold if needed, and add omalizumab if antihistamines fail. However, the guidelines also acknowledge a significant gap in evidence about the safety of these treatments during pregnancy and breastfeeding.²⁵ If you are pregnant or planning to become pregnant while managing CSU, the conversation with your doctor should weigh disease control against the limited safety data, and treatment decisions tend to be more conservative as a result.

The Gut Microbiome Connection

An emerging and still preliminary area of research links CSU to changes in the gut microbiome. Patients with chronic urticaria show altered gut bacteria compared to healthy individuals, including an increased abundance of the Enterobacteriaceae family. These bacteria produce lipopolysaccharide (LPS), a molecule that can promote a particular immune shift favoring Th2 cell differentiation and production of IL-4, a chemical messenger involved in allergic-type inflammation.²⁶ Whether these microbial changes cause or simply accompany CSU is still unclear, and no probiotic or dietary intervention has been proven to treat the condition. But the gut-skin axis is an active area of investigation, and it may eventually offer new angles for therapy in a disease that clearly has roots in immune dysregulation beyond the skin alone.

1
PubMed. Chronic urticaria and the pathogenic role of mast cells ↩︎
2
PubMed. Pathogenesis of Chronic Spontaneous Urticaria With or Without Angioedema ↩︎
3
PubMed Central. Chronic Spontaneous Urticaria: The Devil’s Itch ↩︎
4
PubMed Central. A Practical Approach to Diagnosing and Managing Chronic Spontaneous Urticaria ↩︎
5
PubMed Central. Key differences between chronic inducible and spontaneous urticaria ↩︎
6
PubMed Central. Differential diagnosis between urticarial vasculitis and chronic spontaneous urticaria ↩︎
7
JAMA. Chronic Spontaneous Urticaria: A Review ↩︎
8
PubMed. Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: A systematic review ↩︎
9
PubMed Central. Does chronic urticaria affect quality of sleep and quality of life? ↩︎
10
PubMed Central. Sleep Quality as a Predictor of Quality-of-Life and Emotional Status Impairment in Patients with Chronic Spontaneous Urticaria ↩︎
11
PubMed Central. The burden of chronic spontaneous urticaria is substantial: Real‐world evidence from ASSURE‐CSU ↩︎
12
PubMed. Efficacy and Safety of Up-dosing Antihistamines in Chronic Spontaneous Urticaria: A Systematic Review of the Literature ↩︎
13
PLoS ONE. H1-Antihistamine Up-Dosing in Chronic Spontaneous Urticaria: Patients’ Perspective of Effectiveness and Side Effects – A Retrospective Survey Study ↩︎
14
PubMed. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria ↩︎
15
PubMed Central. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin ↩︎
16
Allergo Journal International. Efficacy and safety of medications for antihistamine-refractory chronic spontaneous urticaria: a systematic review and network meta-analysis ↩︎
17
PubMed. Cyclosporine for Chronic Spontaneous Urticaria: A Meta-Analysis and Systematic Review ↩︎
18
JAMA Dermatology. Dupilumab in Patients With Chronic Spontaneous Urticaria: Phase 3 LIBERTY-CSU CUPID Randomized Clinical Trials ↩︎
19
PubMed Central. Dupilumab as Add-on Therapy for Management of Chronic Spontaneous Urticaria ↩︎
20
Springer Link / Drugs. Update on the Treatment of Chronic Spontaneous Urticaria ↩︎
21
World Allergy Organization Journal. Clinical Evolution of Chronic Spontaneous Urticaria: A 5-Year Prospective Study ↩︎
22
PubMed Central. Clinical Remission of Chronic Spontaneous Urticaria (CSU): A Targeted Literature Review ↩︎
23
Current Treatment Options in Allergy. Biomarkers in Chronic Spontaneous Urticaria: Are We Ready for its Use in Clinical Practice? ↩︎
24
PubMed. Endotypes, phenotypes, and biomarkers in chronic spontaneous urticaria: Evolving toward personalized medicine ↩︎
25
PubMed Central. Urticaria in Pregnancy and Lactation ↩︎
26
PubMed Central. Current insights on gut microbiome and chronic urticaria: progress in the pathogenesis and opportunities for novel therapeutic approaches ↩︎